v3.21.1
Condensed Consolidated Interim Statement of Loss and Comprehensive Loss (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Revenue
Expenses:    
Research and development 8,228 5,934
General and administrative 8,024 5,900
Operating expenses 16,252 11,834
Other income (expense):    
Interest income 27 323
Foreign exchange loss (2) (15)
Total other income 25 308
Net loss and comprehensive loss $ (16,227) $ (11,526)
Basic and diluted loss per common share (in dollars per share) $ (0.18) $ (0.15)
Weighted average number of common shares outstanding used in the calculation of (in thousands)    
Basic and diluted loss per common share (in shares) 88,884 76,227

Source